{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044323","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.944651+00:00","generated_at":"2026-06-07T15:18:10.752235+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon appoints Dr. Sébastien Hazard as EVP and Chief Medical Officer","bullets":["Dr. Hazard joins as EVP and CMO effective Dec. 11, 2023; previously Head of Clinical Development at Bicycle Therapeutics.","Base salary of $475,000, target bonus of 50%; received inducement option for 80,000 shares at $0.88/share and 20,000 restricted shares.","He will oversee clinical programs including IMNN-001 (IL-2) for ovarian cancer; topline data from OVATION 2 Study expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044323","json":"https://secwatch.observer/filing/0001493152-23-044323.json","markdown":"https://secwatch.observer/filing/0001493152-23-044323.md","text":"https://secwatch.observer/filing/0001493152-23-044323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/0001493152-23-044323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:18:10.752235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8dd5579bfb","claim":"Dr. Sébastien Hazard was appointed as Executive Vice President and Chief Medical Officer at Imunon, Inc..","evidence_excerpt":"On December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/0001493152-23-044323-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}